Literature DB >> 22836146

Low nigrostriatal reserve for motor parkinsonism in nonhuman primates.

Samer D Tabbal1, Linlin Tian, Morvarid Karimi, Christopher A Brown, Susan K Loftin, Joel S Perlmutter.   

Abstract

OBJECTIVE: Nigrostriatal reserve refers to the threshold of neuronal injury to dopaminergic cell bodies and their terminal fields required to produce parkinsonian motor deficits. Inferential studies have estimated striatal dopamine reserve to be at least 70%. Knowledge of this threshold is critical for planning interventions to prevent symptom onset or reverse nigrostriatal injury sufficient to restore function in people with Parkinson disease. In this study, we determine the nigrostriatal reserve in a non-human primate model that mimics the motor manifestations of Parkinson disease.
METHODS: Fifteen macaque monkeys received unilateral randomized doses of the selective dopaminergic neuronal toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. We compared blinded validated ratings of parkinsonism to in vitro measures of striatal dopamine and unbiased stereologic counts of nigral neurons after tyrosine hydroxylase immunostaining.
RESULTS: The percent of residual cell counts in lesioned nigra correlated linearly with the parkinsonism score at 2 months (r=-0.87, p<0.0001). The parkinsonism score at 2 months correlated linearly with the percent residual striatal dopamine (r=-0.77, p=0.016) followed by a flooring effect once nigral cell loss exceeded 50%. A reduction of about 14 to 23% of nigral neuron counts or 14% to 37% of striatal dopamine was sufficient to induce mild parkinsonism.
CONCLUSIONS: The nigral cell body and terminal field injury needed to produce parkinsonian motor manifestations may be much less than previously thought.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22836146      PMCID: PMC3443325          DOI: 10.1016/j.expneurol.2012.07.008

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  35 in total

1.  Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.

Authors:  H Bernheimer; W Birkmayer; O Hornykiewicz; K Jellinger; F Seitelberger
Journal:  J Neurol Sci       Date:  1973-12       Impact factor: 3.181

2.  Novel observations with FDOPA-PET imaging after early nigrostriatal damage.

Authors:  R E Yee; I Irwin; C Milonas; D B Stout; S C Huang; K Shoghi-Jadid; N Satyamurthy; L E Delanney; D M Togasaki; K F Farahani; K Delfani; A M Janson; M E Phelps; J W Langston; J R Barrio
Journal:  Mov Disord       Date:  2001-09       Impact factor: 10.338

3.  Influence of age and time interval between death and autopsy on dopamine and 3-methoxytyramine levels in human basal ganglia.

Authors:  A Carlsson; B Winblad
Journal:  J Neural Transm       Date:  1976       Impact factor: 3.575

4.  Time course of nigrostriatal degeneration in parkinson's disease. A detailed study of influential factors in human brain amine analysis.

Authors:  P Riederer; S Wuketich
Journal:  J Neural Transm       Date:  1976       Impact factor: 3.575

5.  In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease.

Authors:  C S Lee; A Samii; V Sossi; T J Ruth; M Schulzer; J E Holden; J Wudel; P K Pal; R de la Fuente-Fernandez; D B Calne; A J Stoessl
Journal:  Ann Neurol       Date:  2000-04       Impact factor: 10.422

Review 6.  Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease.

Authors:  D J Brooks; K A Frey; K L Marek; D Oakes; D Paty; R Prentice; C W Shults; A J Stoessl
Journal:  Exp Neurol       Date:  2003-11       Impact factor: 5.330

7.  Parkinsonian signs and substantia nigra neuron density in decendents elders without PD.

Authors:  G Webster Ross; Helen Petrovitch; Robert D Abbott; James Nelson; William Markesbery; Daron Davis; John Hardman; Lenore Launer; Kamal Masaki; Caroline M Tanner; Lon R White
Journal:  Ann Neurol       Date:  2004-10       Impact factor: 10.422

8.  Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis.

Authors:  J W Langston; P Ballard; J W Tetrud; I Irwin
Journal:  Science       Date:  1983-02-25       Impact factor: 47.728

9.  Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): seven cases.

Authors:  P A Ballard; J W Tetrud; J W Langston
Journal:  Neurology       Date:  1985-07       Impact factor: 9.910

10.  No differential regulation of dopamine transporter (DAT) and vesicular monoamine transporter 2 (VMAT2) binding in a primate model of Parkinson disease.

Authors:  LinLin Tian; Morvarid Karimi; Susan K Loftin; Chris A Brown; HuChuan Xia; JinBin Xu; Robert H Mach; Joel S Perlmutter
Journal:  PLoS One       Date:  2012-02-16       Impact factor: 3.240

View more
  15 in total

Review 1.  Neuroimaging biomarkers for Parkinson disease: facts and fantasy.

Authors:  Joel S Perlmutter; Scott A Norris
Journal:  Ann Neurol       Date:  2014-11-07       Impact factor: 10.422

Review 2.  Dopamine D3 receptor: A neglected participant in Parkinson Disease pathogenesis and treatment?

Authors:  Pengfei Yang; Joel S Perlmutter; Tammie L S Benzinger; John C Morris; Jinbin Xu
Journal:  Ageing Res Rev       Date:  2019-11-22       Impact factor: 10.895

3.  In vivo measures of nigrostriatal neuronal response to unilateral MPTP treatment.

Authors:  LinLin Tian; Morvarid Karimi; Chris A Brown; Susan K Loftin; Joel S Perlmutter
Journal:  Brain Res       Date:  2014-05-15       Impact factor: 3.252

4.  Carboxyfullerene neuroprotection postinjury in Parkinsonian nonhuman primates.

Authors:  Laura L Dugan; LinLin Tian; Kevin L Quick; Josh I Hardt; Morvarid Karimi; Chris Brown; Susan Loftin; Hugh Flores; Stephen M Moerlein; John Polich; Samer D Tabbal; Jonathan W Mink; Joel S Perlmutter
Journal:  Ann Neurol       Date:  2014-07-22       Impact factor: 10.422

Review 5.  PET Imaging in Movement Disorders.

Authors:  Baijayanta Maiti; Joel S Perlmutter
Journal:  Semin Nucl Med       Date:  2018-08-16       Impact factor: 4.446

6.  Validation of nigrostriatal positron emission tomography measures: critical limits.

Authors:  Morvarid Karimi; LinLin Tian; Christopher A Brown; Hubert P Flores; Susan K Loftin; Tom O Videen; Stephen M Moerlein; Joel S Perlmutter
Journal:  Ann Neurol       Date:  2013-02-19       Impact factor: 10.422

7.  Initiation of calorie restriction in middle-aged male rats attenuates aging-related motoric decline and bradykinesia without increased striatal dopamine.

Authors:  Michael F Salvatore; Jennifer Terrebonne; Victoria Fields; Danielle Nodurft; Cori Runfalo; Brian Latimer; Donald K Ingram
Journal:  Neurobiol Aging       Date:  2015-10-19       Impact factor: 4.673

8.  Validation of midbrain positron emission tomography measures for nigrostriatal neurons in macaques.

Authors:  Christopher A Brown; Morvarid K Karimi; LinLin Tian; Hugh Flores; Yi Su; Samer D Tabbal; Susan K Loftin; Stephen M Moerlein; Joel S Perlmutter
Journal:  Ann Neurol       Date:  2013-09-16       Impact factor: 10.422

Review 9.  Neuroimaging of Parkinson's disease: Expanding views.

Authors:  Carol P Weingarten; Mark H Sundman; Patrick Hickey; Nan-kuei Chen
Journal:  Neurosci Biobehav Rev       Date:  2015-09-26       Impact factor: 8.989

10.  Exercise alters resting-state functional connectivity of motor circuits in parkinsonian rats.

Authors:  Zhuo Wang; Yumei Guo; Kalisa G Myers; Ryan Heintz; Yu-Hao Peng; Jean-Michel I Maarek; Daniel P Holschneider
Journal:  Neurobiol Aging       Date:  2014-08-16       Impact factor: 4.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.